Environmental Impact Acquisition Corp.
Environmental Impact Acquisition — GreenLight Biosciences — Investor Presentation (June 2022)
26 slides from Environmental Impact Acquisition's investor presentation, June 2022
Slide 1: Forward-Looking Statements
Forward-Looking Statements This presentation contains and our officers, directors and employees may make “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to GreenLight’s future operations, scienti
Slide 2: GreenLight at work
GreenLight at work ROCHESTER, NY WOBURN, MA SEVILLE, SPAIN Pilot plant for our agriculture Human health discovery, Field research station to accelerate products. Will also support initial research, clinical development transition of research and discovery MAINE commercialization of earliest compound
Slide 3: One tool for One Health: Healthy people and planet through RNA innovation
One tool for One Health: Healthy people and planet through RNA innovation
Slide 4: Exceptional team with diverse public company expertise
Exceptional team with diverse public company expertise Our management team has a proven track record of success 15 Companies Andrey J. Zarur Susan Keefe Carole Cobb Amin Khan Mark Singleton founded Ph.D CEO MBA CFO MBA COO Ph.D Chief Ph.D CCO & GM, Scientific Officer, Plant Health Human Health 8 Com
Slide 5: Our largest challenges are inextricably linked
Our largest challenges are inextricably linked GreenLight offers global, targeted, environmentally-sound solutions Intense population growth Threatened food security Pandemics © 2022 GreenLight Biosciences. All rights reserved. 5
Slide 6: Food security and climate change
Food security and climate change We need new modes of action to efficiently control pests while respecting the environment The problem The dsRNA advantage 1.2 billion tons contributing to 2.2 New mode of action that seeks to increase food productivity while respecting the environment of food is lost
Slide 7: Global health and climate change
Global health and climate change We need better tools to improve global health outcomes The problem The mRNA advantage Pandemics are happening 3x Rapid lead identification and iteration more often increase infectious disease outbreaks (1980 to 2010) Low- and middle- Limited access income countries:
Slide 8: Platform to support RNA design, development, and manufacturing
Platform to support RNA design, development, and manufacturing Proprietary plant health process creates economies of skill; human health pipeline uses separate manufacturing process Regulatory Approval dsRNA Regulatory trials Commercialization design optimization via greenhouse testing Agriculture:
Slide 9: Product innovation is not enough: Must own manufacturing
Product innovation is not enough: Must own manufacturing In addition to product innovation, owning manufacturing innovation provides acceleration and control Protein/Peptide DNA RNA dsRNA and Humanization of AAV delivery vectors & antibodies proprietary payloads mRNA proprietary Interchangeable Nano
Slide 10: Plant and animal health
Plant and animal health ©©2022 2022 GreenLight ConfidentialBiosciences. Information All rights reserved. 10
Slide 11: GreenLight is targeting some of food security's greatest challenges
GreenLight is targeting some of food security’s greatest challenges Our global product portfolio can address key food and agriculture industry concerns By 2050 By 2026 32% Botrytis (2025) Most fruit and vegetables Pollinator (2024) Bee hives Fusarium (2025) Wheat 7 increase in population Product lau
Slide 12: Protect honeybees
Case study: GreenLight is working to help beekeepers Protect honeybees Proprietary solution testing in field trials; EPA submission planned this year The problem: Honeybee colonies in the United States alone contribute to pollinating more than 100 crops annually worth an estimated $15 billion**. But
Slide 13: Protect potatoes
Case study: GreenLight is working to help farmers Protect potatoes RNA solution using foliar application; expected EPA approval this year The problem: Colorado potato beetle causes more than $500 million of damage a year and develops rapid resistance. The solution: Calantha TM Potato fields protecte
Slide 14: Reduce crop loss caused by fungal pathogens
Case study: GreenLight is working to help farmers Reduce crop loss caused by fungal pathogens The problem: Fungal pathogens account for 30% of crop losses globally–enough to feed 600 million people**. Botrytis cinerea The solution: • Causes disease in more Current strategies involve frequent sprayin
Slide 15: Rapid discovery helps address emerging climate-driven farmer pain points
Rapid discovery helps address emerging climate-driven farmer pain points Pipeline stretches from protecting honeybees to fresh produce and large-scale crops, a $6bn addressable market Discovery Greenhouse Confirmatory Regulatory Launch Program Collaborator POC field trials TAM($M) & lab studies tria
Slide 16: Human health
Human health ©©2022 2022 GreenLight ConfidentialBiosciences. Information All rights reserved. 16
Slide 17: GreenLight is targeting global human health challenges
GreenLight is targeting global human health challenges mRNA design flexibility coupled with our production capability can enable rapid development of vaccines and therapies 1 3 $36B pre-Covid vaccine Gene therapy Vaccine market + gene Gene program programs therapy market (*) Therapy (SCD) GreenLight
Slide 18: COVID vaccines for the rest of the world
Case study: COVID vaccines for the rest of the world The world needs more timely and accessible vaccines and therapeutics GreenLight has designs for modular integrated CTA submitted in April 2022 for Phase 1 clinical manufacturing for deployment where appropriate study in South Africa Pre- vs. Post-
Slide 19: Genetic disorders
Case study: Genetic disorders GreenLight is building the tools to enable mRNA-mediated gene therapy The problem: LMICs are excluded from The solution: gene-therapy innovation development GreenLight gene-therapy architecture is working to target Of 179 recruiting or near-recruiting clinical trials fo
Slide 20: Gene therapy for sickle cell disease
Case study: Gene therapy for sickle cell disease GreenLight is building tools to enable mRNA-mediated gene therapy The problem: The solution: Two classes of RNA molecules with distinct purposes Potential mechanism for our gene therapy architecture Sickle cell disease has no GreenLight gene-therapy c
Slide 21: Shingles vaccine, a global addressable market of $5bn
Case study: Shingles vaccine, a global addressable market of $5bn GreenLight is designing a messenger RNA vaccine for shingles for Serum Institute of India The problem: The solution: The world’s largest vaccine manufacturer, Serum Institute of India, chose 95% GreenLight as its partner for Serum’s f
Slide 22: An expanding Human Health pipeline
An expanding Human Health pipeline Our design and manufacturing capabilities enable development of vaccines and therapies Early Clinical Development Application Program Collaborator Pre-clinical Toxicity pre-clinical Phase 1 | Phase 2 | Phase 3 SARS-CoV2 Vaccine (Covid-19) Seasonal Academic Vaccine
Slide 23: World-leading partnerships
World-leading partnerships By working together from the beginning of the research and development process, we serve the medical needs of low- and middle-income countries and ensure local needs are addressed • Serum Institute of India has engaged us to design three messenger RNA products, including a
Slide 24: Promoting sustainable food systems and good health is core to our mission
Promoting sustainable food systems and good health is core to our mission We are committed to ESG responsibilities and to measuring our impact As a public benefit corporation, we are structured and governed to focus on our community, employees, partners, and society generally, as well as shareholder
Slide 25: Join GreenLight's journey
Join GreenLight’s journey Diversified RNA-based Expected 2022 EPA Preparing for Covid-19 pipeline with 7 approval for foliar- vaccine Phase 1 agricultural product applied RNA pesticide, clinical trial in South launches between protecting against Africa 2022 and 2026 Colorado potato beetle Manufactur
Slide 26: Thank you
Thank you 20220614
GreenLight Biosciences — Investor Presentation (June 2022) on 6ix